Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium

[1]  Guido Schwarzer,et al.  General Package for Meta-Analysis , 2015 .

[2]  S. Kato,et al.  Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer , 2015, The American journal of surgical pathology.

[3]  C. Perou,et al.  Defining breast cancer intrinsic subtypes by quantitative receptor expression. , 2015, The oncologist.

[4]  Jamie R. Kutasovic,et al.  Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omics , 2015, Breast Cancer Research.

[5]  Stephen McQuaid,et al.  The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer , 2014, Histopathology.

[6]  A Hollestelle,et al.  Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy , 2014, British Journal of Cancer.

[7]  R. Wiśniowski,et al.  Survival from breast cancer in patients with CHEK2 mutations , 2014, Breast Cancer Research and Treatment.

[8]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[9]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[10]  C. Criscitiello,et al.  Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? , 2013, Ecancermedicalscience.

[11]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Hilsenbeck,et al.  Fibroblast Growth Factor Receptor Signaling Is Essential for Normal Mammary Gland Development and Stem Cell Function , 2013, Stem cells.

[13]  S. Cross,et al.  CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. King,et al.  Response to DNA damage of CHEK2 missense mutations in familial breast cancer. , 2012, Human molecular genetics.

[15]  Lukas Balek,et al.  Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation , 2012, PloS one.

[16]  Lukas Balek,et al.  Receptor Tyrosine Kinases Activate Canonical WNT/?-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct Beta-Catenin Phosphorylation , 2012 .

[17]  J. Lubiński,et al.  Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer , 2012, Breast Cancer Research and Treatment.

[18]  J. Foekens,et al.  Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes , 2012, Breast Cancer Research and Treatment.

[19]  Dimitris Anastassiou,et al.  Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo , 2011, BMC Cancer.

[20]  Päivi Heikkilä,et al.  Variants on the promoter region of PTEN affect breast cancer progression and patient survival , 2011, Breast Cancer Research.

[21]  K. Czene,et al.  Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Jakubowska,et al.  Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Greco,et al.  Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications , 2011, Breast Cancer Research.

[24]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[25]  Patrick Neven,et al.  Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[26]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[27]  J. Hopper,et al.  Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study , 2011, Breast Cancer Research.

[28]  P. Cowin,et al.  Key signaling nodes in mammary gland development and cancer: β-catenin , 2010, Breast Cancer Research.

[29]  C. Perou,et al.  Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. , 2010, Cancer research.

[30]  N. Pavletich,et al.  Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. , 2009, Molecular cell.

[31]  P. Pharoah,et al.  Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? , 2009, British Journal of Cancer.

[32]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jae K Lee,et al.  Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. , 2008, Cancer research.

[34]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Olga Anczuków,et al.  Does the nonsense‐mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? , 2008, Human mutation.

[36]  Patricia L. Harris,et al.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts , 2007, International journal of cancer.

[37]  Gordon K. Smyth,et al.  A comparison of background correction methods for two-colour microarrays , 2007, Bioinform..

[38]  M. Kitagawa,et al.  Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F‐1 after DNA damage , 2007, The EMBO journal.

[39]  J. Peterse,et al.  Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Jakubowska,et al.  A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland , 2007, Breast Cancer Research and Treatment.

[41]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[42]  H. Nevanlinna,et al.  The CHEK2 gene and inherited breast cancer susceptibility , 2006, Oncogene.

[43]  T. Fehm,et al.  Progression-specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas in situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis , 2006 .

[44]  Kay Nieselt,et al.  Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. , 2006, Cancer research.

[45]  F. Bertucci,et al.  Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.

[46]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  A. Ashworth,et al.  Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study , 2005, The Lancet.

[48]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Collas,et al.  Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. , 2005, Molecular biology of the cell.

[50]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[51]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[52]  J. Lubiński,et al.  Pathology of breast cancer in women with constitutional CHEK2 mutations , 2005, Breast Cancer Research and Treatment.

[53]  M. Schutte,et al.  Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant , 2004, Journal of Medical Genetics.

[54]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[55]  Päivi Heikkilä,et al.  CHEK2 variant I157T may be associated with increased breast cancer risk , 2004, International journal of cancer.

[56]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[57]  Thomas Waerner,et al.  Expression profiling of epithelial plasticity in tumor progression , 2003, Oncogene.

[58]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[59]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Stevens,et al.  Chk2 activates E2F-1 in response to DNA damage , 2003, Nature Cell Biology.

[61]  J. Eyfjörd,et al.  Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[62]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[63]  J. H. Ward.  Hierarchical Grouping to Optimize an Objective Function , 1963 .

[64]  D.,et al.  Regression Models and Life-Tables , 2022 .